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Abstract
BACKGROUND: Diabetes mellitus is a chronic metabolic disease characterized by increased blood sugar levels 
(BSLs). Elevated BSL was to be reliably measured by measuring the concentration of hemoglobin glycosylate 
(HbA1C). Chronic hyperglycemia can result in damage to endothelial cells resulting in disruption of vascular 
hemostasis leading to complications in the form of vascular disorders. Endothelial damage or dysfunction will 
increase cytokines, one of which is vascular endothelial growth factor (VEGF), which induces angiogenesis. 
AIM: In our study we wanted to investigate the correlation between serums VEGF with lipid profile at type 2 diabetes 
mellitus patients in primary health care in Medan city of North Sumatera, Indonesia.
MATERIALS AND METHODS: This study conducted at type 2 diabetes mellitus with the cross-sectional analytic 
method. The inclusion criteria of the samples were all the patients diagnosed with type 2 diabetes mellitus, both the 
sexes. Body mass index (BMI), blood pressure, duration of disease, and family history were recorded. The laboratory 
parameters, including fasting blood sugar, HbA1c, high-density lipoprotein, low-density lipoprotein, triglycerides (TG), 
and cholesterol, were examined by Paramita Laboratory Clinic and VEGF and hypoxia-inducible factor (HIF)-1α, we 
examined by ELISA methods in the laboratory Medical Faculty, Universitas Sumatera Utara. The data of the samples 
were processed using a computer with the SPSS program.
RESULTS: There was a significant correlation between VEGF and BMI, TG, and HIF-1α. The statistical analysis 
using correlation test found that there was a significant correlation between VEGF and BMI, TG, HIF-1α type 2 
diabetes mellitus patients (p < 0.005).
CONCLUSION: Therefore, our study showed that the correlation between VEGF and lipid profile (TG), BMI, and 
HIF-1α was a positive correlation, which showed a directional relationship, if the VEGF level is high then the BMI, 
TG and HIF-1α values are also high.
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Introduction
Type 2 diabetes mellitus was a metabolic 
disorder characterized by hyperglycemia and associated 
with deficiency insulin activity or secretion with absolute 
and relative [1]. Because of chronic hyperglycemic and 
insulin resistance caused increasing permeability of blood 
vessel and disorder endothelial cell (EC). Type 2 diabetes 
patients have early development of abnormal endothelial 
function, it caused vasoconstriction, inflammation cell 
accumulated, migration of smooth muscle cell, and 
increased cytokine production, which results in plaque 
development [2]. One of the cytokines secretions is 
the vascular endothelial growth factor (VEGF) which is 
a growth factor that induces angiogenesis in vascular 
ECs [3] and is a significant regulator of angiogenesis in 
both physiological and pathological conditions. VEGF is 
a growth factor that can induce angiogenesis in vascular 
ECs and is a significant regulator of angiogenesis in both 
physiological and pathological conditions [4].
In the angiogenesis process, the most potent 
mitogens acting on ECs are the VEGF and basic fibroblast 
growth factor. The expression of VEGF, which occurs 
under the influence of hypoxia-inducible factor-1 (HIF-1), 
starts and maintains a neovascularization process [5].
Processes occurring in diabetes such as 
hyperglycemia, insulin resistance, hypertension, 
dyslipidemia, central obesity, and impaired NO 
synthesis affect blood flow in the vessels and cause 
tissue hypoxia. Hypoxia is a signal for the induction 
of angiogenesis and the expression of many genes, 
including VEGF and VEGFR2, which, due to their 
functions, may have an impact on the development of 
diabetic complications [6]. Research has shown that 
increased angiogenesis is closely associated with the 
HIF-1α pathway and the HIF-1α/VEGF axis plays a 
pivotal role in tumor angiogenesis [7]. Several types of 
research that demonstrated that serum VEGF levels 
were increased in type 2 diabetes mellitus patients 
with complications [8]. Therefore, VEGF is associated 
with the development of type 2 diabetes mellitus and is 
influenced by various factors. In our study we wanted to 
investigate the correlation between serums VEGF with 
lipid profile at type 2 diabetes mellitus patients in primary 
health care in Medan city of North Sumatera, Indonesia.
B - Clinical Sciences Endocrinology
1132 https://www.id-press.eu/mjms/index
Materials and Methods
In this study, we used 89 of the samples 
with type 2 diabetes mellitus, we recruited them from 
the Primary Health Care in Medan city and Primary 
Health Care in Binjai and Stabat city, North Sumatera, 
Indonesia. This was conducted from May to July 2020. 
Patients with known diabetics taking oral hypoglycemic 
agents or managed with diet or using insulin for 
glycemic control were included in the study. Permission 
from the institutional review committee was obtained. 
Patients were informed with the detail of the study and 
written consent was obtained from the patients before 
they participated in the study. Because of the pandemic 
COVID 19 in our country, we used personal protective 
equipment for prevention of transmission of the viral 
COVID 19 and all the samples used the mask when 
attending to the clinic.
We measured height and weight with the 
subjects standing in light clothes. Body mass index 
(BMI) was calculated as the weight in kilograms 
divided by the square of the height in meters (kg/m2). 
Blood pressure values were taken as the mean of two 
measurements after the subjects had been seated for 
at least 5 min. Subjects fasted overnight to provide 
a blood specimen. Blood samples were collected 
(using syringe) and transferred to Paramitha Clinical 
Laboratory immediately to be conducted fasting blood 
sugar, glycosylated hemoglobin, and lipid profile. In 
the Paramitha Clinical Laboratory the examination of 
fasting blood sugar using hexokinase methods, the 
examination of glycosylated hemoglobin using HPLC 
methods, examination of lipid profile using direct 
CHOD PAP, and GPO PAP methods. We examined the 
glycosylated hemoglobin test for patients because of 
this examination as a gold standard for diabetes mellitus 
patients. VEGF levels were measured with an ELISA 
assay in laboratories in Medical Faculty, Universitas 
Sumatera Utara.
The examination VEGF levels in the serum 
which allows samples to clot for 10–20 min at room 
temperature. Sample concentrations should be 
predicted before being used in the assay and samples 
to be used within 5 days should be stored at 2–8°C. 
Samples should be aliquoted or must be stored at 
−20°C within 1 month or −80°C within 6 months. The 
samples was centrifuged 2000–3000 RPM for 20 min. 
All reagents should be brought to room temperature 
before use. Reconstitute the 120 μl of the standard 
(6400 ng/L) with 120 μl of standard diluent to generate 
a 3200 ng/L standard stock solution. Allow the standard 
to sit for 15 min with gentle agitation before making 
dilutions. Prepare duplicate standard points by serially 
diluting the standard stock solution (3200 ng/L) 1:2 
with standard diluent to produce 1600 ng/L, 800 ng/L, 
400 ng/L, and 200 ng/L solutions. Standard diluent 
serves as the zero standards (0 ng/L). Any remaining 
solution should be frozen at −20°C and used within 1 
month. Dilution of standard solutions suggested is as 
follows: 
3200 ng/L Standard No.5 120 μl Original Standard + 120 μl Standard diluent
1600 ng/L Standard No.4 120 μl Standard No.5 + 120 μl Standard diluent
800 ng/L Standard No.3 120 μl Standard No.4 + 120 μl Standard diluent
400 ng/L Standard No.2 120 μl Standard No.3 + 120 μl Standard diluent
200 ng/L Standard No.1 120 μl Standard No.2 + 120 μl Standard diluent
Dilute 20 ml of wash buffer concentrate 
25× into deionized or distilled water to yield 
500 ml of 1× Wash Buffer. If crystals have formed 
in the concentrate, mix gently until the crystals have 
completely dissolved.
Assay procedure
1. Add 40 μl sample to sample wells and then add 
10 μl anti-VEGF antibody to sample wells, then 
add 50 μl streptavidin-HRP to sample wells 
and standard wells (not blank control well). Mix 
well. Cover the plate with a sealer. Incubate 
60 min at 37°C
2. Remove the sealer and wash the plate 5 times 
with a wash buffer. Soak wells with at least 
0.35 ml wash buffer for 30 s to 1 min for 
each wash. For automated washing, aspirate 
all wells and wash 5 times with wash buffer, 
overfilling wells with wash buffer. Blot the plate 
onto paper towels or other absorbent material
3. Add 50 μl substrate solution A to each well and 
then add 50 μl substrate solution B to each 
well. Incubate plate covered with a new sealer 
for 10 min at 37°C in the dark
4. Add 50 μl stop solution to each well, the blue 
color will change into yellow immediately
5. Determine the optical density (OD value) of 
each well immediately using a microplate 
reader set to 450 nm within 10 min after adding 
the stop solution.
Calculation of result
Construct a standard curve by plotting the 
average OD for each standard on the vertical (Y) axis 
against the concentration on the horizontal (X) axis 
and draw a best fit curve through the points on the 
graph. These calculations can be best performed with 
computer-based curve-fitting software and the best fit 
line can be determined by regression analysis.
Typical data
This standard curve is only for demonstration 
purposes. A standard curve should be generated with 
each assay.
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Figure 1: Standard curve
Statistical analysis
The continuous data were expressed as mean 
± standard deviation (SD). Pearson correlation test was 
used for checking the normality of distribution. If the data 
were normally distributed, the correlation test was used. 
p < 0.05 was considered as statistically significant.
Results
We evaluated clinical and laboratory findings 
in 89 patients with type 2 diabetes mellitus. Of the 
total number of subjects, 22.5% (20) were male, and 
77.5% (69) of the subjects were female. The minimum 
age of the samples 35 years old and the maximum age 
was 79 years old and the median of age 54 years old. 
The minimum of the BMI of the samples was 17.63 
kg/m2 and the maximum 46.44 kg/m2 and the mean 
26.29 kg/m2. The minimum of abdominal circumference 
was 98 cm and the maximum 216 cm and the mean 
92.69 cm and SD 10.47 cm. The minimum of blood 
pressure of systole and diastole 98 mmHg and 60 
mmHg and maximum 216 mmHg and 113 mmHg 
with means value 150.96 mmHg and 87.75 mmHg 
and SD 22.048 and 10.444 mmHg. The minimum of 
blood sugar level (BSL) of the sample 73 mg/dL and 
the maximum of BSL levels was 610 mg/dL and the 
mean of value 283.55 mg/dL and SD 137.428 mg/dL. 
The minimal glycated hemoglobin (HbA1C) value 
4.7% and maximum value 14.7% with the mean 
value of 9.1% and SD value 2.72%. The minimum 
HIF-1α levels were 0.52 ul/dL and the maximum was 
13.45 ul/dL and the mean was 1.93 ul/dL and SD 
2.46 ul/dL. The minimum VEGF levels of the samples 
were 111.64 ul/dL and the maximum was 22052.61 
ug/dL and the mean was 931.4882 ug/dL and SD 
2405.95 ug/dL (Tables 1 and 2).
Table 1: Characteristics of the sample
Characteristic Mean Median Minimum Maximum SD
Age (years) 55.20 54 35 79 8.92
BMI (kg/m2) 26.2972 24.5600 17.63 46.44 5.61078
Abdominal circumference (cm) 92.69 91.00 68 121 10.470
Blood pressure (systole) mmHg 150.96 150 98 216 22.048
Blood pressure (diastole) mmHg 87.75  86 60 113 10.444
BMI: Body mass index.
Correlations between VEGF and other 
variables
In our study, using statistic we assessed the 
core relationships between serum VEGF levels and 
other variables in all the type 2 diabetes mellitus patients 
and found that the serum VEGF level was positively 
associated with the triglyceride (TG) value (r = 0.255, 
p < 0.05), cardiac risk index (r = 0.238, p ≤ 0.005), HIF-1α 
(r = 0.659, p < 0.005), and BMI (r = 0.271, p < 0.05).
Table 2: Metabolic markers
Marker n Minimum Maximum Mean Std. deviation
BMI 89 17.63 46.44 26.2972 5.61
LP 89 68 121 92.69 10.47
TDS 89 98 216 150.96 22.05
TDD 89 60 113 87.75 10.44
BSL 89 73 610 283.55 137.43
Hba1c 89 4.70 14.70 9.1011 2.72
Cholesterol 89 136 335 220.55 42.06
LDL 89 51 249 126.43 34.7
HDL 89 24 77 46.69 11.68
TG 89 77 708 244.37 124.04
Durasi 89 1 18 4.44 4.25
VEGF 89 111.64 22052.61 931.4882 2405.95
VEGF: Vascular endothelial growth factor, BSL: Blood sugar level, HbA1c: Glycated hemoglobin,  
HDL: High-density lipoprotein, LDL: Low-density lipoprotein, TG: Triglycerides, BMI: Body mass index.
However, we found no significant correlation 
ships between VEGF and any of the following factors: 
Sex, age, HbA1c, BSL, high-density lipoprotein-
cholesterol (HDL-C), and low-density lipoprotein-
cholesterol (LDL-C). We can see in the bellow Table 3.
Table 3: Correlation between VEGF and other variables
Variable P R
Age 0.36 0.098
Gender 0.417 0.087
BMI 0.041 0.217*
Abdominal circumference (cm) 0.166 0.148
Blood pressure (systole) mmHg 0.702 0.041
Blood pressure (diastole) mmHg 0.384 0.093
BSL 0.983 0.002
Hba1c 0.849 −0.020
Cholesterol 0.897 −0.14
LDL-C 0.591 −0.058
HDL-C 0.048 −0.211
TG 0.016 0.255*
Cardiac risk index 0.024 0.238*
Durasi 0.464 −0.079
HIF-1α 0.00 0.659**
VEGF: Vascular endothelial growth factor, BSL: Blood sugar level, HbA1c: Glycated hemoglobin, 
HDL: High-density lipoprotein-cholesterol, LDL: Low-density lipoprotein-cholesterol, TG: Triglycerides, 
BMI: Body mass index.
Discussion
There were more females (77.5%) than males 
(22.5%) with type 2 DM in this study. The high proportion 
of females in this study may be due to the nature of the 
population admitting to primary health care in that more 
of them seek medical attention than men under the 
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favor of having more free time because most of them 
were housewives. This aim of the study to evaluate the 
correlation between VEGF with lipid profile (cholesterol, 
LDL, HDL and Triglyceride) and other marer metabolic 
at type 2 diabetes mellitus patients.
An important risk factor for type 2 diabetes 
is obesity and strongly related disorders of lipid 
parameters. It is estimated that dyslipidemia occurs in 
60–80% of diabetic patients [9]. Angiogenesis is a key 
factor in adipogenesis [10]. The previous study reports 
the positive correlation between serum TG levels and 
VEGF, which is consistent with the study by Peczyńska 
et al. (2004), which reported patients with incipient 
diabetic angiopathy [11]. Mahdy et al. (2010) also 
noted a positive correlation between lipid parameters 
(total cholesterol and LDL-C) in patients with type 2 
diabetes [12]. Besides, Wada et al. (2011) also noted 
a positive correlation between serum TG and VEGF-A 
levels [13].
In my study, we found that there was a 
significant and positive correlation between VEGF 
with TG, the high TG concentration, so the high VEGF 
concentration too in my study, we found that there was 
no significant correlation between VEGF and cholesterol 
total, LDL, and HDL. Like research by Martynova et al. 
reported that high TGs were associated with high serum 
VEGF [14]. However, different research by Sun et al. 
that there were no significant relationships between 
VEGF and any of the following factors such as sex, 
age, BMI, HbA1c, FBG, TG, TC, HDL-C, and LDL-C at 
type 2 DM [15]. In this study, we found that there was 
a significant and positive correlation between VEGF 
and BMI over a large range of BMI 17.63 kg/m2 and 
46.44 kg/m2. Previous studies indicate that overweight 
and obese individuals display elevated serum VEGF 
levels and a statistical BMI dependence of VEGF 
levels in normal-weight subjects within a wide variance 
of male and female participants at different metabolic 
states [16]. The other research reported a positive 
correlation between plasma VEGF concentrations and 
BMI over a large range of BMI between 17.6 kg/m2 and 
43.6 kg/m2 [17]. The same with our study the samples 
with the lowest BMI 17.63 kg/m2 which was the low 
weight and 46.44 kg/m2 was the obese category. And 
there was positive correlation BMI with VEGF. Although 
the research has stated that there was a positive 
correlation between VEGF and BMI, how the role of 
VEGF in the pathogenesis of obesity was unclear, 
Type 2 diabetes mellitus whose pathogenesis is tightly 
linked to increased BMI [18], it has been shown that the 
insulin sensitivity is decreased [19] suggesting a direct 
negative relationship between VEGF concentrations 
and insulin sensitivity.
Research by Zehetner showed at the 
retinopathy diabetic patients that HbA1c levels 
revealed a significant correlation with plasma VEGF 
concentrations [20] and the other research showed 
that VEGF levels in plasma were positively correlated 
with glycemic control indicators (FBG and HbA1c) [21] 
as we know that the fundamental regulator most 
widely known to be involved in angiogenesis is VEGF. 
VEGF is also associated with tumor progression and 
poor outcomes in various human cancers [22]. In 
cultured ECs, VEGF has been proven to be induced 
by elevated levels of glucose and advanced glycation 
end-products [23]. However, in my study, we found 
that there was no significant correlation VEGF with 
Hba1c and BSL, the same with research by Sun X 
reported that there were no significant relationships 
between VEGF with glycemic control (HbA1c, FBG). 
There are other reasons because VEGF is affected 
by several factors, including gender, smoking, hyper- 
and hypoglycemia, elevated blood lipids, hypoxia, 
and activated stress axes, but the major stimulant is 
cellular hypoxia [24].
The expression of VEGF, which occurs 
under the influence of HIF1, starts and maintains a 
neovascularization process [5]. It has become evident 
that hypoxia plays an important role in all diabetic 
vascular complications [25]. This research found that 
that there was a significant and positive correlation 
between VEGF and HIF-1α that mean the high 
HIF-1α concentration and expressed the high VEGF 
concentration. Research by Jiang et al. showed that 
the serum levels of VEGF, HIF-1α, and IGF-I were 
significantly higher in diabetic patients than in the 
controls and there were positive correlations existed 
between VEGF and HIF-1α [26].
Figure 2: Dilution of the samples
Conclusion
In our study showed that there was a significant 
and positive correlation between VEGF and lipid profile 
(TG), BMI, and HIF-1α.
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